Scientists toss another Alzheimer’s program into the scrap heap as PhII fails
While a legion of scientists have been employed in failed attempts to clear away the toxic tangles of proteins often found in the brains of Alzheimer’s patients, another set have continued to plug away at the various chemicals that play a role in orchestrating the brain’s complex cellular communications system.
But that’s proved just as frustrating.
Today, Boehringer Ingelheim threw in the towel on an Alzheimer’s program for a drug called BI 409306, another effort to see if they could do a better job in modulating glutamate, one of those neurotransmitters that can run amuck in dementia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.